Active, not recruitingPhase 2NCT05456685
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Studying OBSOLETE: Primary peritoneal serous/papillary carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Mirvetuximab soravtansine(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2022 – 2026
Study locations (30)
- University of Arizona Cancer Center /ID# 268906, Tucson, Arizona, United States
- Women'S Cancer Research Network - Cogi /ID# 268912, Fresno, California, United States
- Providence - St. Jude Medical /ID# 268911, Fullerton, California, United States
- Moores Cancer Center /ID# 268888, La Jolla, California, United States
- USC Norris Comprehensive Cancer Center /ID# 268964, Los Angeles, California, United States
- University of California Los Angeles Medical Center /ID# 268883, Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian /ID# 268907, Newport Beach, California, United States
- UC Davis Comprehensive Cancer Center /ID# 269085, Sacramento, California, United States
- Scripps Md Anderson - Prebys Cancer Center /ID# 268966, San Diego, California, United States
- California Pacific Medical Center - Van Ness Campus /ID# 268886, San Francisco, California, United States
- Smilow Cancer Hospital at Yale New Haven /ID# 268889, New Haven, Connecticut, United States
- AdventHealth Orlando /ID# 268920, Orlando, Florida, United States
- Sarasota Memorial Hospital /ID# 268882, Sarasota, Florida, United States
- Moffitt Cancer Center /ID# 269089, Tampa, Florida, United States
- Winship Cancer Institute of Emory University /ID# 268913, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05456685 on ClinicalTrials.govOther trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06856499Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06994195A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian CancerSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGPHASE2NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesAbbVie
- RECRUITINGNANCT06969833Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaCentre Oscar Lambret
- RECRUITINGPHASE3NCT05659381Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerGOG Foundation
- RECRUITINGNANCT05597683Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal ChemotherapyGangnam Severance Hospital
- RECRUITINGPHASE3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)Genelux Corporation
- ACTIVE NOT RECRUITINGPHASE2NCT05406674Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian CancerThe Netherlands Cancer Institute
See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →